Haresh SelvaskandanMBChB · PhD
Publications

Full bibliography — 80+ peer-reviewed outputs across nephrology, AI, and clinical medicine.

Including publications in Nature Reviews Nephrology and Kidney International.

Book Chapters

3 entries
2024
IgA Nephropathy
Selvaskandan H, Barratt J. GlomPedia, July 2024
2024
Chronic Kidney Disease, Proteinuria & Haematuria
Selvaskandan H, Hull K, Barratt J. Best of Five MCQs for the ESE(Neph), Oxford University Press, 2024
2022
IgA Nephropathy & Henoch–Schönlein Purpura
Selvaskandan H, Cheung CK, Barratt J. Primer on Nephrology, Springer, 2022

Reviews

19 entries
2026
Glomerular frontiers: consensus perspectives from GlomCon Hawaii 2025
Ebrahimi N, Poyan Mehr A, Selvaskandan H et al. Rare Kidney Diseases · May 2026;1(2)
2025
IgA Nephropathy: a paradigm shift in treatment strategies
Roberts L, Jones M, Barratt J, Selvaskandan H. Curr Opin Nephrol · 2025;34(5):381–388
2025
IgA Nephropathy: an overview of active clinical trials
Ghozloujeh Z, Selvaskandan H, Wiegley N et al. Kidney Med · 2025;7(10):101708
2025
The pathogenesis of IgA nephropathy and implications for treatment
Cheung CK, Alexander S, Reich HN, Selvaskandan H et al. Nature Reviews Nephrology · 2025;(1):9–23
2024
IgA Nephropathy: Emerging mechanisms of disease
Roberts L, Williams C, Barratt J, Oni L, Selvaskandan H. Indian J Nephrology · 2024;34(4):297–309
2024
Primary IgA Nephropathy: new insights and emerging therapies
Selvaskandan H, Jhevari K, Rizk D. Adv Kidney Dis Health · 2024;31(3):180–193
2024
A review of focal segmental glomerulosclerosis classification with a focus on genetic associations
Bonilla M, Efe O, Selvaskandan H, Lerma EV, Wiegley N. Kidney Med · 2024;6(6):100826
2024
Technological innovations to improve patient engagement in nephrology
Selvaskandan H, Gee PO, Seethapathy H. Adv Kidney Dis Health · 2024;31(1):28–36
2023
Novel paradigms in treatment: IgA nephropathy
Selvaskandan H, Barratt J, Cheung CK. Kidney International Reports · 2023;9(2):203–213
2023
IgA nephropathy: an overview of drug treatments in clinical trials
Selvaskandan H, Gonzalez-Martin G, Barratt J, Cheung CK. Expert Opin Investig Drugs · 2023
2022
Clinical application of microRNAs in glomerular diseases
Selvaskandan H, Pawluczyk I, Barratt J. Nephrol Dial Transplant · 2022;gfac230
2022
Immunological drivers of IgA nephropathy: exploring the mucosa–kidney link
Selvaskandan H, Cheung CK, Barratt J. Journal of Immunogenetics · 2022;49(1):8–21
2022
New insights into the pathogenesis and treatment strategies in IgA nephropathy
Scionti K, Molyneux K, Selvaskandan H, Barratt J, Cheung CK. Glomerular Diseases · 2022;2:15–29
2021
Managing crescentic IgA nephropathy
Selvaskandan H. ASN Kidney · 2021;13(12):20–21
2021
The non-coding RNA landscape in IgA nephropathy — where are we in 2021?
Pawluczyk I, Selvaskandan H, Barratt J. Journal of Clinical Medicine · 2021;13(5):e15270
2020
Monitoring immune responses in IgA nephropathy: biomarkers to guide management
Selvaskandan H, Shi S, Twaij S, Cheung CK, Barratt J. Frontiers in Immunology · 2020;11:572754
2019
New strategies and perspectives in treating IgA nephropathy
Selvaskandan H, Cheung CK, Muto M, Barratt J. Clin Exp Nephrol · 2019;23(5):577–588
2018
MicroRNAs: a new avenue to understand, investigate and treat IgA nephropathy?
Selvaskandan H, Pawluczyk I, Barratt J. Clinical Kidney Journal · 2018;11(1):29–37
2017
IgA nephropathy: driving innovation with a rare renal disease registry
Selvaskandan H, Dillon M, Barratt J. Journal of Kidney Care · 2017;2(4):205–211

Original Research

12 entries
2026
The characterisation of loin pain in IgA nephropathy
Newman K, Barratt J, Szklarzewicz J, Roberts L, Thomas R, Mellon L, Smith A, Gale D, Wong K, RaDaR, Selvaskandan H. Kidney International Reports · 2026 (accepted for publication)
2025
B-cell derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathy
Pawluczyk IZA, Bachu JS, Brown JR, Lacey M, Mbadugha C, Straatman K, Wimbury D, Selvaskandan H, Barratt J. Kidney International · 2025;108(1):119–135
2024
Different vaccine platforms result in distinct antibody responses to the same antigen in haemodialysis patients
Wall N, Lamerton R, Ashford F, Perez-Toledo M, Jasiulewicz, Banham G, Newby M, Faustini S, Richter A, Selvaskandan H, et al. Vaccines · 2024;13(1):7
2024
Examining the association between serum galactose-deficient IgA1 and primary IgA nephropathy: a systematic review and meta-analysis
Vaz de Castro PAS, Amaral AA, Almeida MG, Selvaskandan H, Barratt J, Simões e Silva AC. J Nephrol · 2024
2022
Risk factors associated with COVID-19 severity among patients on maintenance haemodialysis: a retrospective multi-centre cross-sectional study
Selvaskandan H, Hull KL, Adenwalla SF, Ahmed S, Cusu MC, Graham-Brown M, Gray L, Hall M, Hamer R, Kanbar A, Kanji H, Lambie M, Lee HS, Mahdi K, Major RW, Medcalf JF, Natarajan S, Oseya B, Stringer S, Tabinor M, Burton JO. BMJ Open · 2022;12(5):e054869
2022
Regional variations in nephrology trainee confidence with clinical skills may relate to the availability of local training opportunities in the UK
Selvaskandan H, Baharani J, Hamer R. Clinical and Experimental Nephrology · 2022
2022
Burnout and Long COVID among the UK nephrology workforce: results from a national survey
Selvaskandan H, Nimmo A, Savino M, Afuwape S, Brand S, Graham-Brown M, Medcalf J, Cockwell P, Beckwith H. Clinical Kidney Journal · 2022;15(3):517–526
2021
A pilot study to predict risk of IgA nephropathy progression based on miR-204 expression
Pawluczyk I, Nicholson M, Barbour S, Er L, Selvaskandan H, Bhachu JS, Barratt J. Kidney International Reports · 2021;6(8):2179–2188
2021
An ethnic variation in the acceptance of biologic disease-modifying therapies: a university hospital experience
Selvaskandan H, Moorthy A. Cureus · 2021;13(5):e15270
2021
Seroprevalence of antibody to S1 spike protein following vaccination against COVID-19 in patients receiving haemodialysis
Billany RE, Selvaskandan H, Adenwalla SF, Hull KL, March DS, Burton JO, Bishop NC, Carr EJ, Beale R, Tang JW, Bird PW, Holmes CW, Baines R, Brunskill NH, Graham-Brown MPM. Kidney International · 2021;99(6):1492–1494
2020
Macrophage interactions with collecting duct epithelial cells drive tubulointerstitial inflammation and fibrosis in IgA nephropathy
Pawluczyk I, Soares M, Barratt W, Brown J, Bhachu J, Selvaskandan H, Zeng Y, Sarania R, Molyneux K, Roberts I, Barratt J. Nephrol Dial Transplant · 2020;35(11):1865–1877
2016
Acoustic trauma slows AMPAR-mediated EPSCs in the auditory brainstem reducing GluA4 subunit expression as a mechanism to rescue binaural function
Pilati N, Linley D, Selvaskandan H, Uchitel O, Hennig M, Kopp-Scheinpflug C, Forsythe ID. Journal of Physiology · 2016;594(13):3683–3703

Case Reports

5 entries
2022
Acute respiratory distress syndrome driven by severe hypercalcaemia and acute kidney injury
Selvaskandan H, Hull K, Gregory R, Pan D, Macriyiannis T, Briggs J, Richards C, Mason C, Jesus-Silva J, Bell R. Clin Nephrol Case Stud · 2022;10:21–27
2020
Inhibition of the lectin pathway of the complement system as a novel approach in the management of IgA vasculitis-associated nephritis
Selvaskandan H, Cheung CK, Dormer J, Martinez M, Xu G, Barratt J. Nephron · 2020;144(9):453–458
2019
Diabetic myonecrosis in end-stage renal disease
Selvaskandan H, Amablawaner K, Westacott R. Clin Nephrol Case Stud · 2019;7:41–45
2019
High-dose oral linezolid achieved rapid clinical and microbiological recovery in a severely overweight male with long-standing infected ulcers
Selvaskandan H, Denton-Beaumont R, Hamilton R. J Antimicrob Chemother · 2019;74(6):1755–1757
2019
Microangiopathic haemolytic anaemia in a young female
Selvaskandan H, Karavadra M, Paramasperan K, Glasby M, Iyasere O. Kidney International · 2019;95(5):1277–1278

Editorials

5 entries
2025
Should histology guide treatment decisions in IgA nephropathy?
Selvaskandan H, Seethapathy H. Kidney International Reports · 2025;10(11):3270–3723
2024
The COVID-19 vaccination and IgA nephropathy: further cause for reassurance
Selvaskandan H, Barratt J. Kidney International · 2024;5(9):1229–1231
2024
The microbiome and IgA nephropathy: a new avenue for treatment?
Selvaskandan H, Barratt J. Kidney International · 2024
2024
Dynamic individualised risk prediction in IgA nephropathy: entering the era of artificial intelligence
Selvaskandan H, Barratt J. Clin J Am Soc Nephrol · 2024;19(7):826–828
2024
Charting new frontiers in IgA nephropathy: a paradigm shift toward precision medicine and early intervention?
Selvaskandan H, Barratt J. Kidney International · 2024;105(4):659–661

Letters

5 entries
2021
Impact of the COVID-19 pandemic on training, morale and well-being amongst the UK renal workforce
Beckwith H, Nimmo A, Savino M, Selvaskandan H, Graham-Brown MPM, Medcalf J, Cockwell P. Kidney International Reports · 2021;6(5):1433–1436
2020
The exclusion of patients with chronic kidney disease in prospectively registered interventional trials for COVID-19
Major RW, Selvaskandan H, Makkeyah Y, Hull KL, Kurverji A, Graham-Brown MPM. Journal of the American Society of Nephrology · 2020
2014
View from here: Prescribing Skills Assessment
Selvaskandan H, Baheerathan A. Clinical Teacher · 2014;11(1):58–59
2014
View from here: Smartphones & medical education
Baheerathan A, Selvaskandan H. Clinical Teacher · 2014;11(6):485–486
2013
The importance of counselling in young, female epileptic patients
Baheerathan A, Selvaskandan H. J Paediatr Neurosci · 2013;8(3):265

Published Abstracts

13 entries
2025
#715 Loin pain in adults with IgA nephropathy: insights from qualitative interviews with patients, families, and healthcare professionals
Newman K… Selvaskandan H. Nephrology Dialysis Transplantation · Vol 40, Suppl 3, Oct 2025, gfaf116.0260
2025
Toward Consensus on Glomerular Disease Centers of Excellence: results from a Delphi Panel Study (SA-PO0794)
Norouzi S… Selvaskandan H… Poyan Mehr A. JASN · 36(10S), Oct 2025; 10.1681/ASN.2025wtrh1cge
2025
Loin pain in rare kidney disease: analysis of 3,867 questionnaire responses with linked data from the UK national registry of rare kidney diseases (RaDaR)
Wong K, Newman K, Selvaskandan H, et al. KI Reports · 2025;10(2):S230–321
2024
Exploring the impact of loin pain in IgA nephropathy: a UK-wide mixed-methods qualitative study
Newman K, …, Selvaskandan H. JASN · 2024
2024
Towards an IgA nephropathy atlas
Saez-Rodriguez J, Barratt J, Selvaskandan H, Duivenvoorden R, Kretzler M, Mariani L, Berthier C, Witsap A, Olafsson H, Wenerson A, Gesualdo L, Nystrom J. KI Reports · 2024;9(Suppl4):177–178
2023
Can artificial intelligence predict the need for acute renal replacement therapy among inpatients with acute kidney injury?
Selvaskandan H, Gaultney T, Heath D, Linfoot S, Xu G. Future Healthc J · 2023;10(Suppl 3):19–20
2023
Digital spatial profiling can be used to study glomerular endothelial cells in IgA nephropathy
Selvaskandan H, Boys C, Pawluczyk I, Barratt J. Nephrol Dial Trans · 2023;38(1)
2023
WCN23-0066: Identifying druggable pathways in IgA nephropathy using spatial transcriptomics
Selvaskandan H, Pawluczyk I, Barratt J. KI Reports · 2023;8(3):S49–50
2023
WCN23-0139: Leveraging modern machine-learning tools to predict outcomes of in-patient acute kidney injury
Selvaskandan H, Gauntley T, Heath D, Linfoot S, Xu G. KI Reports · 2023;8(3):S98
2023
Can artificial intelligence predict the need for acute renal replacement therapy among in-patients with acute kidney injury?
Selvaskandan H, Gauntley T, Heath D, Linfoot S, Xu G. Future Healthcare Journal · 2023
2018
Macrophage-derived products induce pro-inflammatory and pro-fibrotic responses in renal collecting ducts: a potential role in the pathogenesis of IgA nephropathy
Pawluczyk I, Selvaskandan H, Zeng Y, Sarania R, Barratt J. Kidney Diseases · 2018;4(3):126
2018
Is there an ethnic variation in the acceptance of biologic therapy among patients with axial spondyloarthropathy?
Selvaskandan H, Moorthy A. Rheumatology · 2018;57:key075.307
2017
Ethnic variation in the acceptance of biologic therapy among rheumatology patients — a university hospital experience
Selvaskandan H, Al-Ani H, Moorthy A. Annals of the Rheumatic Diseases · 2017;76:1436

Affiliated Trial Publications

23 entries
2026
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY)
RECOVERY Collaborative Group. Lancet Infect Dis · Jan 2026;(1):34–35
2025
Quantifying association of early proteinuria and eGFR changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis (UK RaDaR)
RaDaR Consortium. Kidney International · 2025;108(3):455–469
2025
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY)
RECOVERY Collaborative Group. The Lancet · Sep 2025
2024
Description and cross-sectional analyses of 25,880 adults and children in the UK National Registry of Rare Kidney Diseases cohort
RaDaR Consortium. Kidney Int Rep · 2024;9(7):2067–2083
2024
Effect of rare kidney diseases on kidney failure: a longitudinal analysis of the UK RaDaR cohort
RaDaR Consortium. The Lancet · 2024
2024
Phase 2 trial of cemdisiran in adults with IgA nephropathy: a randomised controlled trial
Cemdisiran Phase 2 Investigators and Collaborators. Clin J Am Soc Nephrol · 2024
2024
Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome (PIMS-TS, MIS-C; RECOVERY)
RECOVERY Collaborative Group. Lancet Child Adolesc Health · 2024;8(3):190–200
2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
PROTECT Investigators. The Lancet · 2023
2023
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY)
RECOVERY Collaborative Group. Lancet Diabetes Endocrinol · 2023
2023
Higher-dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY)
RECOVERY Collaborative Group. The Lancet · 2023
2023
Sparsentan in patients with IgA nephropathy: a pre-specified interim analysis from a randomised, double-blind, active-controlled phase 3 trial
PROTECT Investigators. The Lancet · 2023
2023
IgA nephropathy patient baseline characteristics in the Sparsentan PROTECT study
PROTECT Investigators. KI Reports · 2023
2022
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY)
RECOVERY Collaborative Group. The Lancet · 2022;400(10349):359–368
2022
Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients
Haemodialysis COVID-19 Consortium. The Lancet · 2022;399(10327):800–802
2022
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY)
RECOVERY Collaborative Group. The Lancet · 2022;399(10325):665–676
2022
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY)
RECOVERY Collaborative Group. The Lancet · 2022;399(10320):143–151
2021
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
Haemodialysis COVID-19 Consortium. The Lancet · 2021
2021
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY)
RECOVERY Collaborative Group. The Lancet · 2021
2021
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY)
RECOVERY Collaborative Group. The Lancet · 2021;397(10285):1637–1645
2021
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY)
RECOVERY Collaborative Group. The Lancet · 2021;397(10274):605–612
2020
Effect of hydroxychloroquine in hospitalised patients with COVID-19
RECOVERY Collaborative Group. New England Journal of Medicine · 2020;383(21):2030–2040
2020
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY)
RECOVERY Collaborative Group. The Lancet · 2020;396(10259)
2020
Dexamethasone in hospitalised patients with COVID-19: preliminary report
RECOVERY Collaborative Group. New England Journal of Medicine · 2020
Connect

Open to industry collaboration on glomerular disease, clinical trials, and AI in nephrology.

Email — hs328@le.ac.uk → Connect on LinkedIn Download Full CV